Precocious Puberty Treatment Market

Precocious Puberty Treatment Market Snapshot (2023 to 2033)

The global precocious puberty treatment market is anticipated to attain an impressive valuation of USD 1,716.43 million in 2023 and is projected to reach USD 3,650.66 million by 2033, trailing a CAGR of 7.8% during the forecast period.

Rising focus of key players on research to develop novel drugs and expand the indication label of currently available drugs for treatment of precocious puberty is anticipated to fuel the precocious puberty treatment market growth during the forecast period.

On the other hand, the number of children suffering from hormonal disorders is increasing due to various types of inherited factors and abnormal functioning of endocrine glands. These hormonal disorders mainly growth hormone disorder led the children to adopt early puberty symptoms which affects the height and other growth phenomenon in children.

Thus, augmenting market growth. Moreover, with the rising prevalence of overactive growth hormone, children are more likely to suffer from precocious puberty. This suggests that rising prevalence of hormonal disorders are anticipated to fuel the precocious puberty treatment market growth during the forecast period.

Data Points	Key Statistics
Expected Market Value (2023)	USD 1,716.43 million
Anticipated Forecast Value (2033)	USD 3,650.66 million
Projected Growth Rate (2023 to 2033)	CAGR 7.8%

2018 to 2022 Precocious puberty treatment management Demand Analysis vs. Forecast 2023 to 2033

The market for precocious puberty treatment was worth USD 1,310 million in 2018, while growing at a CAGR of 5.5 % during the historical period. The market's growth is driven by an increase in the number of research and development activities. This will offer lucrative opportunities for growth in the precocious puberty treatment market during the projected period. Moreover, increasing drug approvals and launches will further drive growth of this market.

Similarly, increasing investments for the development of advanced technologies and surging number of emerging markets will further provide beneficial opportunities for precocious puberty treatment market growth during the forecast period. On the other hand, higher effectiveness of triptorelin in the suppression of gonadotropin in Central Precocious Puberty (CPP) among young boys and girls is anticipated to propel precocious puberty treatment market growth.

For example, according to data published in the Scientific World Journal, in May 2012, triptorelin 11.25 mg per 90 days efficiently suppressed the pituitary-gonadal level in children with central precocious puberty from first administration. This will create more space and opportunities for market expansion. After a comprehensive analysis of above-mentioned factors, the industry for precious puberty treatment is projected to be worth USD 3650.66 million by end of the forecast period.

Which are Some Prominent Drivers of the Precocious puberty treatment market?

Use of approved therapies will propel treatment market of precocious puberty

The use of Triptodor (triptorelin), Lupron Depot-Ped (leuprolide acetate), and Supprelin LA (histrelin acetate) in treatment of precocious puberty are anticipated to fuel growth in this market. These gonadotropin-releasing hormone (GnRH) agonists are approved therapies used in treating central precocious puberty.

These agonists are used to prolong the suppression of gonadotropin secretion when required which is expected to augment the market growth. Moreover, use of triptorelin, a GnRH agonist, effectively suppresses the pituitary-gonadal axis and pubertal development in children affected with precocious puberty that is also estimated to propel growth in the market of precocious puberty treatment during the projected period. The increasing prevalence of hormonal disorders is expected to positively influence the market growth. Also, the rising incidences of obesity will propel growth during the forecast period.

Another crucial factor driving growth rate of precocious puberty treatment market is the increasing healthcare expenditure which helps in enhancing its infrastructure. Moreover, increasing initiatives by public and private organizations to spread awareness are also expected to expand precocious puberty treatment market. High disposable income and rising demand for disease-specific treatments will also result in the expansion of precocious puberty treatment market. Similarly, increasing use of radiation or chemotherapy for treatment of cancer and sedentary lifestyle of people will drive the market in the forecast period.

What are the Challenges Projected to be Faced by the Market?

High cost of treatment and lack of skilled professionals to hold back market growth

The high cost associated with the treatment is projected to restrain market growth. The lack of skilled professionals and dearth of healthcare infrastructure in developing economies will challenge the precocious puberty treatment market during the forecast period.

Furthermore, a drop in clinical visits due to COVID-19 outbreak and dearth of awareness among people will also act as restrain and will further obstruct growth market during the forecast period.

Region-Wise Insights

What are the growth prospects in North America?

North America to dominate the market with maximum share

The demand for treatment options of precocious puberty in North America is projected to be maximum in the forecast period. This region is expected to dominate the market by reaching USD 1,704.8 million by end of the forecast period. This region is estimated to possess 46.7% market share by end of 2033 with CAGR of 7.1% during the forecast period.

North America is expected to hold a dominant position in the global central precocious puberty market over the forecast period, due to the growing availability of drugs for the treatment of precocious puberty in this region. For example, in October 2017, Arbor Pharmaceuticals, LLC and Debiopharm International SA declared the commercial availability of Triptodur in the region for the treatment of pediatric patients aged two years and older who are diagnosed with central precocious puberty (CPP). This development will benefit the market in the long run.

The growth is also attributed to rising clinical trials and proliferation in research development activities for prevention of hormonal misbalance among the children. In this region, the United States is dominating the market because of the increasing prevalence of obesity leading to early puberty among the children.

What is the growth outlook in East Asia?

East Asian market driving growth with fastest CAGR

The market of precocious puberty treatment in East Asia is estimated to witness fastest CAGR of 7.6% during the forecast period. This region is anticipated to possess 25% market share by end of 2033. Furthermore, market in this region will be worth USD 912.6 million by end of the projected period.

The growth is attributable to factors such as presence of vast number of companies and increasing acceptance of treatment related to early puberty. In this region, Japan is dominating the growth of East-Asia precocious puberty treatment market due to rising prevalence of precocious puberty and rising girl population in this region.

Category wise Insights

By Drug Class, which segment will possess Market Dominance?

Triptorelin will fuel growth with maximum market share

This segment is anticipated to withhold 62% market share by end of the forecast period. This segment will also witness fastest CAGR growth of 9% during the forecast period. The growth is attributed to factors such as use of triptorelin as a first line therapy in treatment of precocious puberty. A new triptorelin 11.25 mg long depot formulation is now available for the treatment of precocious puberty which is regarded as the best treatment for girl child till date. The 3-month depot triptorelin is a satisfactory alternative for the therapy of children affected with precocious puberty. The rising adoption of this alternative in treating this disease is propelling the growth of this segment. Moreover, the longer intervals between injections during the period of therapy may increase acceptability and compliance with treatment. These factors are expected to fuel growth of this segment by 2033.

By Distribution Channel, which segment is expected to dominate the Market?

Hospitals pushing growth with significant market share

The hospital segment dominated the market of precocious puberty treatment in 2022, with a market share of 48.75%. This segment is anticipated to sustain its dominance by accounting for more than 58% market share by end of the forecast period. This segment will grow with a moderate CAGR of 6.1% during the projected period.

The growth is attributed to factors such as high availability of skilled professionals in hospitals and robust and organized healthcare infrastructure. Moreover, easy access of gonadotropin-releasing hormone agonist for treating precocious puberty disorder in these facilities will propel growth of this segment during the forecast period.

Start-ups in Precocious Puberty Treatment Market

Start-ups help in understanding the growth outlook of any industry. These new companies have the potential to generate high returns which directly benefits the growth of any market. These start-ups are naturally more efficient at converting inputs into outputs with more flexibility and adaptability in nature, able to shift quickly in response to volatile market conditions. Some of the start-ups that will fuel the expansion of precocious puberty treatment market are:

• Medivation is a San Francisco, United States-based company that acquires early-development stage pharmaceuticals, develop those product candidates, and then partner or sell successful programs to larger companies. Their pipeline involves enzalutamide, an androgen receptor inhibitor authorized for use in the reatment of metastatic castration-resistant prostate cancer It is being further developed for earlier stages of prostate cancer, progressive breast cancer and hepatocellular carcinoma. Similarly, Talazoparib (MDV3800), an oral drug poly-ADP ribose polymerase, or PARP, inhibitor presently is in Phase 3 clinical trial for gBRCA mutated breast cancer (i.e., advanced breast cancer in patients whose BRCA genes possess germline mutations). They are targeting numerous other solid tumor indications in including breast (beyond gBRCA mutations), prostate, ovarian cancers, small cell lung, and Pidilizumab (MDV9300), an antibody with immune-mediated anti-tumor effects, licensed from CureTech in 2014, in development for diffuse large B-cell lymphoma and other hematologic malignancies, like multiple myeloma. This start-up was granted total funding of USD 100 million.
• Valera Pharmaceuticals (formerly called Hydro Med Sciences) is a Denver, United States-based start-up. This company was founded in 2000. This is a specialty pharmaceutical company focused on developing products to treat urology and endocrinology disorders. Based on its Hydron technology, it is creating a soft, compact, and flexible hydrogel-based implants which can be designed to release therapeutic agents at a controlled rate. Utilizing this technology, it has marketed product Vantas, a palliative treatment of advanced prostate cancer. It also has multiple products in clinical development including Supprelin-LA for precocious puberty. In December 2006, Indevus acquired Valera for a value of USD 120 Million. It is granted funding of USD 30.5 million until now from Psilos Group, Wheatley Partners.
• Indevus Pharmaceuticals is a Malvern, United States-based specialty pharmaceutical company and engaged in the acquisition and development of drugs to treat conditions in urology and endocrinology. The approved products of this company include SanActura (R) and Sanctura XRTM for overactive bladder, Supprelin (R) LA for central precocious puberty, and Delatestryl (R) to treat male hypogonadism. Its developmental stage drugs include Valstartm for bladder cancer, Pro 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens. In January 2009, the company was acquired by

Market Competition

The precocious puberty treatment market is extremely competitive and consists of various key market players. These players are developing novel delivery systems for treating precocious puberty. This is anticipated to fuel precocious puberty treatment market. The key players in this market are: Teva Pharmaceutical Industries Ltd, AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc, Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, Sun Pharmaceutical Industries Limited, and Sanofi S.A.

Key industry players are inclined on adoption of inorganic growth strategies like acquisition, partnerships, and collaboration in order to bolster their product portfolio. This is expected to propel the global precocious puberty treatment market.

• In June, 2020, Ipsen Pharma underwent strategic partnership with Debiopharm for Decapeptyl (triptorelin) for another 15 years. Decapeptyl (triptorelin) is used for treating central precocious puberty in children. This strategic merger helped the company to maintain a continuous product access to patients.
• In March 2022, Accord BioPharma, the United States special division of Intas Pharmaceuticals, Ltd. declared the United States launch of CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of progressive prostate cancer in adults.
• In February 2022, BDR Pharmaceuticals revealed its brand ENZALUTAMIDE, an antiandrogen in 160mg with brand name BDENZA for treatment of Prostate Cancer patients.
• In January 2019, Debiopharm Group informed about an agreement with Allergan to begin a transition process for Trelstar (Triptorelin pamoate) intended to lead to new licensees taking over the commercialization of Trelstar in the United States and Canada and the termination of Allergan's partnership with Debiopharm for strategic reasons.

Report Scope

Report Attribute	Details
Market Value in 2023	USD 1,716.43 million
Market Value in 2033	USD 3,650.66 million
Growth Rate	CAGR of 7.8% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Drug Class, Distribution Channel, Region
Regions Covered	North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa
Key Countries Profiled	United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled	Teva Pharmaceutical Industries Ltd; AbbVie Inc.; Arbor Pharmaceuticals, LLC; Pfizer Inc.; Tolmar Pharmaceuticals, Inc.; Endo International Plc.; Ipsen Pharma; Debiopharm Group; Sun Pharmaceutical Industries Limited; Sanofi S.A
Customization	Available Upon Request

Key Segments Profiled in the Precocious Puberty Treatment Industry Survey

By Drug Class:

• Leuprorelin
• Histrein
• Triptorelin
• Nafarelin

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa

Frequently Asked Questions

How Big is the Precocious Puberty Treatment Market?

The market is valued at USD 1,716.43 million in 2023.

How is the Market’s Historical Performance?

From 2018 to 2022, the market registered a 5.5 % CAGR.

What is the Projected Size of the Precocious Puberty Treatment Market?

By 2033, the market is likely to reach USD 3,650.66 million.

What is the Growth Potential of the Precocious Puberty Treatment Market?

The market is estimated to record a CAGR of 7.8% from 2023 to 2033.

What is the CAGR for North America’s Market?

North America’s market is expected to register a 7.1% CAGR until 2033.